Alembic Pharma Q3 FY25 Results: PAT Drops 23.29% Due to Market Headwinds

Alembic Pharma reported a 23.29% year-on-year (Y-o-Y) drop in its profit after tax (PAT) for Q3 FY25, with PAT standing at ₹138.42 crore, down from ₹180.45 crore in Q3 FY24. The company’s revenue from operations increased by 3.8% Y-o-Y, reaching ₹1,692.74 crore in Q3 FY25, up from ₹1,630.57 crore in the same quarter last year.

Reason for Decline

Alembic’s Managing Director, Shaunak Amin, explained that the drop in PAT was due to market headwinds in the acute segment. He also mentioned that efforts to improve field force efficiency through automation and artificial intelligence (AI) impacted quarterly growth.

Operating Performance

At the operating level, Alembic’s earnings before interest, tax, depreciation, and amortisation (EBITDA) rose to ₹271 crore, with an adjusted EBITDA margin of 16%. This was a slight increase from ₹269 crore and a 16.5% margin in the same quarter last year.

Performance in Key Segments

Alembic’s India branded business grew by 3% to ₹614 crore, largely driven by a 22% growth in its animal health business. In its international business, the US generics segment grew by 10% to ₹521 crore, while the ex-US business also saw a 10% increase to ₹299 crore.

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is involved in creating, producing, and selling pharmaceutical products, including formulations and active ingredients. The company operates 3 research and development centres and 5 manufacturing plants.

Alembic Pharmaceuticals share price is trading at ₹898.00, down by ₹9.30 (1.03%) today as of 11:57 AM IST. The stock opened at ₹900.00, reached a high of ₹913.80, and a low of ₹890.00. The markecapitalisationon stands at ₹17.66K crore, with a P/E ratio of 27.31 and a dividend yield of 1.22%. The 52-week high is ₹1,303.90, and the 52-week low is ₹823.40.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.